Gene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient. 

Market Analysis and Insights: Global Gene Therapy in Oncology Market
The global Gene Therapy in Oncology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Therapy in Oncology market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Therapy in Oncology market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy in Oncology market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy in Oncology market.

Global Gene Therapy in Oncology Scope and Market Size
Gene Therapy in Oncology market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Therapy in Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Ex Vivo
In Vivo

Segment by Application
Hospitals
Diagnostics Centers
Research Institutes

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bristol-Myers Squibb
Cold Genesys
Advantagene
Amgen
AstraZeneca
Bio-Path Holdings
CRISPR Therapeutics
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck
Mologen AG
Oncolytics Biotech
Oncosec
Oncotelic
Shenzhen SiBiono GeneTech
Sillajen Biotherapeutics
Tocagen
UniQure
Ziopharm Oncology